Zobrazeno 1 - 10
of 49
pro vyhledávání: '"Andrew M. Hess"'
Autor:
Andrew M. Hess
Publikováno v:
Creativity and Innovation Management. 31:559-572
Publikováno v:
AIAA SCITECH 2023 Forum.
Autor:
Megan F. Hess, Andrew M. Hess
Publikováno v:
Accounting Horizons. 34:109-124
SYNOPSIS In this study, we investigate the relation between accounting failure and innovation at multiple levels in an organization by developing and testing a model for how top executives and functional managers might change their risk preferences a
Autor:
David A. Kessler, Andrew M. Hess, Keith Obenschain, David C. Eder, Alice Koniges, Anthony Knutson, Graham V. Candler, Heath Johnson, Spencer Starr, Joel Bretheim, Kevin Roe, Eric J. Nielsen, Aaron Walden, Gabriel Nastac, Kevin Jacobson, Roy Campbell, David R. McDaniel, Ryan B. Bond
Publikováno v:
AIAA SCITECH 2022 Forum.
Autor:
David A. Kessler, Andrew M. Hess, Keith Obenschain, David C. Eder, Alice Koniges, Anthony Knutson, Graham V. Candler, Heath Johnson, Spencer Starr, Joel Bretheim, Kevin Roe, Eric J. Nielsen, Aaron Walden, Gabriel Nastac, Kevin Jacobson, Roy Campbell, David R. McDaniel, Ryan B. Bond
Publikováno v:
AIAA SCITECH 2022 Forum.
Autor:
Gabriel B. Goodwin, Evan W. Hyde, David A. Kessler, Camilo Aguilera Munoz, David Miklosovic, Jonathan Sosa, Andrew M. Hess
Publikováno v:
AIAA Propulsion and Energy 2021 Forum.
Publikováno v:
AIAA Propulsion and Energy 2021 Forum.
Autor:
Jonathan Sosa, Ryan F. Johnson, Andrew M. Hess, Gabriel B. Goodwin, Camilo Aguilera, David A. Kessler
Publikováno v:
AIAA Scitech 2021 Forum.
Autor:
Andrew M. Hess, Frank T. Rothaermel
Publikováno v:
IEEE Transactions on Engineering Management. 59:65-76
We present an analysis of the trends and patterns documenting the role of intellectual human capital in the emergence of knowledge within both new biotech ventures and incumbent pharmaceutical firms. We leverage individual-level data detailing the pu
Autor:
Andrew M. Hess, Frank T. Rothaermel
Publikováno v:
Strategic Management Journal. 32:895-909
To answer the question of when are assets complementary, we investigate specific resource combinations along the value chain, focusing on two mechanisms that are central to combining resources for innovation in the pharmaceutical industry: recruitmen